Loading
Starting a bispecific T-cell engager (teclistamab, glofitamab, epcoritamab, tarlatamab) at a tiny dose and increasing it over the first week, so T cells are switched on gradually and the fever-and-low-blood-pressure reaction (cytokine release syndrome) stays mild. The hospital stay it needs has slowed community adoption.
Bispecific T-cell engagers (teclistamab, glofitamab, epcoritamab, tarlatamab) are given in step-up doses over the first week, often with steroid or tocilizumab premedication and inpatient monitoring, after which CRS risk falls sharply and dosing can continue in clinic. The requirement for hospital beds during step-up has slowed community adoption and motivates subcutaneous formulations, prophylactic tocilizumab and outpatient protocols. Venetoclax uses a similar five-week ramp-up in CLL to prevent tumour lysis syndrome.
Backbone ribbon from PDB 12ER. RCSB PDB 12ER. The ribbon widens where the chain is folded into a regular pattern and narrows where it is a loose loop.
Showing the molecule this term concerns: Teclistamab.
Shares Elranatamab, Teclistamab, Cytokine release syndrome (CRS), Relapsed or refractory multiple myeloma.
Shares Tarlatamab, Extensive-stage small-cell lung cancer, Bispecific antibodies, T-cell engagers (bispecific).
Shares Tarlatamab, Extensive-stage small-cell lung cancer, Bispecific antibodies, T-cell engagers (bispecific).
Shares Elranatamab, Teclistamab, Cytokine release syndrome (CRS), Relapsed or refractory multiple myeloma.
Shares Teclistamab, ICANS (neurotoxicity), Cytokine release syndrome (CRS), Bispecific antibodies.
Shares Elranatamab, Relapsed or refractory multiple myeloma, T-cell engagers (bispecific).
Shares Epcoritamab, Glofitamab, ICANS (neurotoxicity), Cytokine release syndrome (CRS).
Shares Tarlatamab, Extensive-stage small-cell lung cancer, T-cell engagers (bispecific).